CytoSorbents Corp CTSO
About Quantitative Ratings
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings. Companies with quantitative ratings are not formally covered by a Morningstar analyst, but are statistically matched to analyst-rated companies, allowing our models to calculate a quantitative moat, fair value, and uncertainty rating.
News
-
CytoSorbents Announces New Data Presentations at Upcoming International Conferences in Cardiac Surgery and Critical Care
-
CytoSorbents Regains Compliance with Nasdaq Minimum Bid Price Requirement
-
CytoSorbents to Present at the H.C. Wainwright 28th Annual Global Investment Conference
-
CytoSorbents Announces Reverse Stock Split
-
CytoSorbents Announces New Real-World Data Demonstrating Significant Reduction in Severe Bleeding Using CytoSorb in CABG Patients on Ticagrelor and Updates Recent DrugSorb-ATR FDA Pre-Submission Meetings
-
CytoSorbents Reports Second Quarter 2026 Financial Results, Recent Business Highlights, and Regulatory Update
Trading Information
- Previous Close Price
- $6.01
- Day Range
- $5.22–5.96
- 52-Week Range
- $2.84–17.20
- Bid/Ask
- $5.12 / $5.99
- Shares Outstanding
- 3.15M
- Market Cap
- $16.61M
- Volume/Avg
- 43,056 / 30,183
Key Statistics
- Price/Earnings (Normalized)
- —
- Price/Sales
- 0.44
- Dividend Yield (Trailing)
- 0.00%
- Dividend Yield (Forward)
- 0.00%
- Dividend Payment Schedule
- —
- Total Yield
- —
Company Profile
CytoSorbents Corp is a leader in blood purification for the treatment of life-threatening conditions in the intensive care unit and cardiac surgery. CytoSorbent's proprietary blood purification technologies are based on biocompatible, high-porous polymer beads that can actively remove toxic substances from blood and other bodily fluids by pore capture and surface adsorption. CytoSorbent's technologies are used in several broad applications. Specifically, two important applications are: the removal of blood thinners during and after cardiothoracic surgery to reduce the risk of severe bleeding, and the removal of inflammatory agents and toxins in common critical illnesses that can cause massive inflammation, organ failure, and patient death. Geographically, in the USA, Germany, and Others.
- Sector
- Healthcare
- Industry
- Medical Devices
- Stock Style Box
- Small Value
- Total Number of Employees
- 129
- Website
- https://www.cytosorbents.com
Valuation
|
Metric
|
CTSO
|
|---|---|
Price/Earnings (Normalized) | — |
Price/Book Value | — |
Price/Sales | 0.44 |
Price/Cash Flow | — |
Price/Earnings
No chart available
Financial Strength
|
Metric
|
CTSO
|
|---|---|
Quick Ratio | 0.47 |
Current Ratio | 0.66 |
Interest Coverage | −4.97 |
Quick Ratio
CTSO
Profitability
|
Metric
|
CTSO
|
|---|---|
Return on Assets (Normalized) | −24.22% |
Return on Equity (Normalized) | −187.51% |
Return on Invested Capital (Normalized) | −21.67% |
Return on Assets
CTSO
Medical Devices Industry Comparables
|
1-Day Chart
|
Name
|
Price
|
Morningstar Rating for Stocks
|
Capital Allocation
|
Economic Moat
|
Market Cap
|
|---|---|---|---|---|---|---|
| Abbott Laboratories
ABT
| LOCK|k^VL&x< | LOCK|&S#V | $179B | |||
| Medtronic PLC
MDT
| LOCK|jHB>lC | LOCK|!<n& | $122B | |||
| Stryker Corp
SYK
| LOCK|<lkT#M% | LOCK|Yz | $118B | |||
| Boston Scientific Corp
BSX
| LOCK|xGWcx& | LOCK|!%@# | $66B | |||
| Edwards Lifesciences Corp
EW
| LOCK|n$$YGms | LOCK|GXLc^ | $51B | |||
| GE HealthCare Technologies Inc Common Stock
GEHC
| LOCK|QN>k@Y | LOCK|$N | $32B | |||
| DexCom Inc
DXCM
| LOCK|vBV@GZ!M | LOCK|QVGf | $29B | |||
| Koninklijke Philips NV ADR
PHG
| LOCK|q!h | LOCK|&T | $26B | |||
| Steris PLC
STE
| LOCK|LTps!#G | LOCK|N!#wX | $23B | |||
| Zimmer Biomet Holdings Inc
ZBH
| LOCK|X<?lG#YD | LOCK|cr | $19B |
United States